Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax	$ (145,311)	$ (964,645)	$ (518,254)	$ (1,084,636)
Amortization of intangible assets			636,061
Acceleration of Auxilium employee equity awards at closing				37,600
Asset impairment charges	93,504	923,607	263,080	1,000,850
Acquisition-related and integration items	19,476	(27,688)	80,201	51,177
Loss on extinguishment of debt	0	40,909	0	41,889
Costs associated with unused financing commitments	0	64,281	0	78,352
Other than temporary impairment of equity investment	0	0	0	18,869
Severance costs	14,800	20,800	30,000	58,100
Remaining lease obligations net of sublease income				7,900
Transaction costs	7,900	52,600	55,400	134,800
Change in fair value of contingent consideration	11,600	(80,300)	24,790	(83,605)
2016 US Generic Pharmaceuticals Restructuring
Segment Reporting Information [Line Items]
Restructuring expenses			13,398
2016 US Generic Pharmaceuticals Restructuring | Inventory Write-Offs
Segment Reporting Information [Line Items]
Restructuring expenses			33,300
2016 US Generic Pharmaceuticals Restructuring | Other Restructuring Costs
Segment Reporting Information [Line Items]
Restructuring expenses	3,900		16,100
Segment Reconciling Items
Segment Reporting Information [Line Items]
Corporate unallocated costs	159,123	137,180	473,933	363,298
Amortization of intangible assets	211,548	121,503	636,061	333,759
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans	14,208	42,919	111,787	131,783
Upfront and milestone payments to partners	1,770	9,261	5,875	14,063
Separation benefits and other cost reduction initiatives	9,782	22,669	70,412	70,256
Impact of Voltaren® Gel generic competition	0	0	(7,750)	0
Acceleration of Auxilium employee equity awards at closing	0	0	0	37,603
Certain litigation-related charges, net	18,256	0	28,715	19,875
Asset impairment charges	93,504	923,607	263,080	1,000,850
Acquisition-related and integration items	19,476	(27,688)	80,201	51,177
Loss on extinguishment of debt	0	40,909	0	41,889
Costs associated with unused financing commitments	0	64,281	0	78,352
Other than temporary impairment of equity investment	0	0	0	18,869
Foreign currency impact related to the remeasurement of intercompany debt instruments	(114)	(5,693)	1,558	(23,991)
Other, net	167	(10,484)	(2,903)	(6,153)
Segment Reconciling Items | 2016 US Generic Pharmaceuticals Restructuring | Inventory Write-Offs
Segment Reporting Information [Line Items]
Restructuring expenses	(9,000)		24,300
Operating Segments
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax	$ 382,409	$ 353,819	$ 1,142,715	$ 1,046,994